Advertisement

The Financial Costs of Headache

  • Francesco Saverio MenniniEmail author
  • Lara Gitto
Chapter
Part of the Headache book series (HEAD)

Abstract

Previous chapters in this section have described the multiple aspects of headache-attributed burden and methods by which many of these may be quantified. This chapter addresses financial costs as an important component of headache-attributed burden. It explains some principal aspects of the methodology of health economic studies on headache and presents the findings of key studies.

Keywords

Absenteeism Presenteeism Direct costs Indirect cost Top-down approach Bottom-up approach Cost of illness Eurolight European Brain Council International Burden of Migraine Study 

References

  1. 1.
    Institute for Health Metrics and Evaluation. The global burden of disease: generating evidence, guiding policy. 2010. http://www.healthdata.org/gbd.
  2. 2.
    GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.CrossRefGoogle Scholar
  3. 3.
    Clarke CE, MacMillan L, Sondhi S, Wells NEJ. Economic and social impact of migraine. Quart J Med. 1996;89:77–84.CrossRefGoogle Scholar
  4. 4.
    Rasmussen BK. Epidemiology and socio-economic impact of headache. Cephalalgia. 1999;19(Suppl 25):20–3.CrossRefGoogle Scholar
  5. 5.
    Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18:385.CrossRefGoogle Scholar
  6. 6.
    Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. PharmacoEconomics. 1997;11(Suppl 1):1–10.CrossRefGoogle Scholar
  7. 7.
    Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20–8.CrossRefGoogle Scholar
  8. 8.
    Stewart WF, Lipton RB, Kolodner K, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41–52.CrossRefGoogle Scholar
  9. 9.
    Steiner TJ. Lipton RB on behalf of Lifting The Burden: the Global Campaign against Headache. The Headache-Attributed Lost Time (HALT) Indices: measures of burden for clinical management and population-based research. J Headache Pain. 2018;19:12.Google Scholar
  10. 10.
    Migraine in America. The hidden costs of migraine. 2016. https://migraine.com/infographic/the-hidden-cost-of-care.
  11. 11.
    Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703–43.CrossRefGoogle Scholar
  12. 12.
    Payne KA, Varon SF, Kawatam AK, Yeomans K, Wilcox TK, Manack Adams A, et al. The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia. 2011;31:1116–30.CrossRefGoogle Scholar
  13. 13.
    Mennini FS, Gitto L, Martelletti P. Improving care through health economics analyses: cost of illness and headache. J Headache Pain. 2008;9:199–206.CrossRefGoogle Scholar
  14. 14.
    Akobundu E, Ju J, Blatt L, Daniel Mullins C. Cost-of-illness studies. A review of current methods. PharmacoEconomics. 2006;24:869–90.CrossRefGoogle Scholar
  15. 15.
    Fishman P, Von Korff M, Lozano P, Hecht J. Chronic care costs in managed care. Health Aff. 1997;16:239–47.CrossRefGoogle Scholar
  16. 16.
    Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007;49:368–74.CrossRefGoogle Scholar
  17. 17.
    Mennini FS, Gitto L, Marcellusi A, Sakai F, Arakawa I. Economics of headache. In: Martelletti P, Steiner TJ, editors. Handbook of headache: practical management. Milan: Springer; 2011.Google Scholar
  18. 18.
    Sanderson JC, Devine EB, Lipton RB, Bloudek LM, Varon SF, Blumenfeld AM, et al. Headache-related health resource utilisation in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013;84:1309–17.CrossRefGoogle Scholar
  19. 19.
    Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, et al. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 2014;15:3.CrossRefGoogle Scholar
  20. 20.
    Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58:700–14.CrossRefGoogle Scholar
  21. 21.
    Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF. Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2003;43:343–52.CrossRefGoogle Scholar
  22. 22.
    Lofland JH, Frick KD. Workplace absenteeism and aspects of access to health care for individuals with migraine headache. Headache. 2006;46:563–76.CrossRefGoogle Scholar
  23. 23.
    Burton WN, Landy SH, Downs KE, Runken MC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009;84:436–45.CrossRefGoogle Scholar
  24. 24.
    Holroyd KA, Stensland M, Lipchik GL, Hill KR, O’Donnell FS, Cordingley G. Psychosocial correlates and impact of chronic tension-type headaches. Headache. 2000;40:3–16.CrossRefGoogle Scholar
  25. 25.
    Smith AP. Acute tension-type headaches are associated with impaired cognitive function and more negative mood. Front Neurol. 2016;7:42.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med. 1997;39:320–7.CrossRefGoogle Scholar
  27. 27.
    Science Daily. 86 million workdays lost to migraine in the UK every year. 2018. https://www.sciencedaily.com/releases/2018/04/180427144727.htm.
  28. 28.
    Serrano D, Manack A, Reed ML, Buse DC, Varon SF, Lipton RB. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health. 2013;16:31–8.CrossRefGoogle Scholar
  29. 29.
  30. 30.
    Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813–8.CrossRefGoogle Scholar
  31. 31.
    Barron R, Carlsen J, Duff SB, Burk C. Estimating the cost of an emergency room visit for migraine headache. J Med Econ. 2003;6:43–53.CrossRefGoogle Scholar
  32. 32.
    Cerbo R, Pesare M, Aurilia C, Rondelli V, Barbanti P. Socio-economic costs of migraine. J Headache Pain. 2001;2:S15–9.CrossRefGoogle Scholar
  33. 33.
    Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med. 2004;46:398–412.CrossRefGoogle Scholar
  34. 34.
    Stewart WF, Wood GC, Razzaghi H, Reed ML, Lipton RB. Work impact of migraine headaches. J Occup Environ Med. 2008;50:736–45.CrossRefGoogle Scholar
  35. 35.
    The Eurolight project. 2012. http://www.eurolight-online.eu.
  36. 36.
    Jönsson B. General principles of disease-costing. In: Olesen J, Steiner T, Lipton R, editors. Reducing the burden of headache. Oxford: Oxford University Press; 2003. p. 211–7.Google Scholar
  37. 37.
    Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.CrossRefGoogle Scholar
  38. 38.
    Jones G. How often were you absent? A review of the use of self-reported absence data. J Appl Psychol. 1994;79:574–91.CrossRefGoogle Scholar
  39. 39.
    Olesen J, Freund TF. European brain council: partnership to promote European and national brain research. Trends Neurosci. 2006;29:493–5.CrossRefGoogle Scholar
  40. 40.
    Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B on behalf of the CDBE2010 study group and the European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155–62.CrossRefGoogle Scholar
  41. 41.
    Stovner LJ, Andrée C. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain. 2008;9:139–46.CrossRefGoogle Scholar
  42. 42.
    Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51:1058–77.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.CEIS Economic Evaluation and HTA (EEHTA), and IGF Department, Faculty of EconomicsUniversity “Tor Vergata”RomeItaly
  2. 2.Institute for Leadership and Management in HealthKingston UniversityKingstonUK
  3. 3.CEIS Economic Evaluation and HTA (EEHTA), Faculty of EconomicsUniversity “Tor Vergata”RomeItaly

Personalised recommendations